Close Menu

NEW YORK – Euroimmun will sell Oncgnostics'cervical cancer test in parts of Europe under an agreement announced on Thursday.

Euroimmun, a PerkinElmer subsidiary, will sell the GynTect test in Portugal, Italy, Turkey, and Poland. Financial and other terms of the deal were not disclosed.

Germany-based Oncgnostics added that it expects the test to be approved by regulators in Canada and to be sold there by the end of the year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.